trial

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCTId NCT00690170
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by Yale University
Primary completion 2009-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2002-12
Primary completion
2009-06
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
KetaminenicotineKetamine and Nicotine

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2009-06
Status
COMPLETED
relationships
The graph out of here
drug
Ketamine
drug
nicotine
drug
Ketamine and Nicotine
drug
lead_sponsor
Yale University
company
indication
Schizophrenia
indication
Cognition Disorders
indication
Healthy Subjects
indication
investigator
Deepak C D'Souza, M.D.
person